Limits...
REVERSE 5-year follow up: CRT impact persists.

ElMaghawry M, Farouk M - Glob Cardiol Sci Pract (2014)

Bottom Line: The role of cardiac resynchronization therapy (CRT) in patients presenting with mild manifestations of heart failure (HF), depressed left ventricular ejection fraction (LV EF), and wide QRS complex, has been addressed in four previous trials: MIRACLE ICD II,(1) MADIT-CRT,(2) RAFT,(3) and REVERSE.(4) The consistent observed benefits in reverse cardiac remodelling and reduction of heart failure adverse events have resulted in guideline recommendations for CRT in NYHA Class II patients.The guidelines also recommend further studies to determine whether survival is increased by CRT in patients with mild symptoms.The 5-year analysis of the REsynchronization reVErses Remodeling Systolic left vEntricular (REVERSE) trial, which was designed prospectively for 5-year follow-up to specifically assess the long term benefits of CRT, were recently published in the European Heart Journal.(5).

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Aswan Heart Centre, Kasr ElHajjar, Aswan, Egypt.

ABSTRACT
The role of cardiac resynchronization therapy (CRT) in patients presenting with mild manifestations of heart failure (HF), depressed left ventricular ejection fraction (LV EF), and wide QRS complex, has been addressed in four previous trials: MIRACLE ICD II,(1) MADIT-CRT,(2) RAFT,(3) and REVERSE.(4) The consistent observed benefits in reverse cardiac remodelling and reduction of heart failure adverse events have resulted in guideline recommendations for CRT in NYHA Class II patients. The guidelines also recommend further studies to determine whether survival is increased by CRT in patients with mild symptoms. The 5-year analysis of the REsynchronization reVErses Remodeling Systolic left vEntricular (REVERSE) trial, which was designed prospectively for 5-year follow-up to specifically assess the long term benefits of CRT, were recently published in the European Heart Journal.(5).

No MeSH data available.


Related in: MedlinePlus

Left ventricular end-systolic volume index, left ventricular end-diastolic volume index (A), and left ventricular ejection fraction (B) over the follow up period of 60 months.2
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4352678&req=5

fig1: Left ventricular end-systolic volume index, left ventricular end-diastolic volume index (A), and left ventricular ejection fraction (B) over the follow up period of 60 months.2

Mentions: The five-year follow up analysis was confined to 419 subjects randomized to CRT ON, who received up to 5 years of CRT therapy. The mean follow up time was 54.8 ± 13.0 months. After 2 years, the functional and LV remodelling were maximal. The 6-min hall walk increased by 18.8 ± 102.3 minutes and the Minnesota and Kansas City scores improved by 8.2 ± 17.8 and 8.2 ± 17.2 unites, respectively. The mean decrease in left ventricular end-systolic volume index and left ventricular end-diastolic volume index was 23.5 ± 34.1 mL/m2 and 25.4 ±  37.0 mL/m2 and the mean increase in LVEF 6.0 ± 10.8% with sustained improvement thereafter (Figure 1). The annualized and 5-year mortality was 2.9 and 13.5% and the annualized and 5-year rate of death or first HF hospitalization 6.4, and 28.1%. The 5-year LV-related complication rate was 12.5%.5


REVERSE 5-year follow up: CRT impact persists.

ElMaghawry M, Farouk M - Glob Cardiol Sci Pract (2014)

Left ventricular end-systolic volume index, left ventricular end-diastolic volume index (A), and left ventricular ejection fraction (B) over the follow up period of 60 months.2
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4352678&req=5

fig1: Left ventricular end-systolic volume index, left ventricular end-diastolic volume index (A), and left ventricular ejection fraction (B) over the follow up period of 60 months.2
Mentions: The five-year follow up analysis was confined to 419 subjects randomized to CRT ON, who received up to 5 years of CRT therapy. The mean follow up time was 54.8 ± 13.0 months. After 2 years, the functional and LV remodelling were maximal. The 6-min hall walk increased by 18.8 ± 102.3 minutes and the Minnesota and Kansas City scores improved by 8.2 ± 17.8 and 8.2 ± 17.2 unites, respectively. The mean decrease in left ventricular end-systolic volume index and left ventricular end-diastolic volume index was 23.5 ± 34.1 mL/m2 and 25.4 ±  37.0 mL/m2 and the mean increase in LVEF 6.0 ± 10.8% with sustained improvement thereafter (Figure 1). The annualized and 5-year mortality was 2.9 and 13.5% and the annualized and 5-year rate of death or first HF hospitalization 6.4, and 28.1%. The 5-year LV-related complication rate was 12.5%.5

Bottom Line: The role of cardiac resynchronization therapy (CRT) in patients presenting with mild manifestations of heart failure (HF), depressed left ventricular ejection fraction (LV EF), and wide QRS complex, has been addressed in four previous trials: MIRACLE ICD II,(1) MADIT-CRT,(2) RAFT,(3) and REVERSE.(4) The consistent observed benefits in reverse cardiac remodelling and reduction of heart failure adverse events have resulted in guideline recommendations for CRT in NYHA Class II patients.The guidelines also recommend further studies to determine whether survival is increased by CRT in patients with mild symptoms.The 5-year analysis of the REsynchronization reVErses Remodeling Systolic left vEntricular (REVERSE) trial, which was designed prospectively for 5-year follow-up to specifically assess the long term benefits of CRT, were recently published in the European Heart Journal.(5).

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Aswan Heart Centre, Kasr ElHajjar, Aswan, Egypt.

ABSTRACT
The role of cardiac resynchronization therapy (CRT) in patients presenting with mild manifestations of heart failure (HF), depressed left ventricular ejection fraction (LV EF), and wide QRS complex, has been addressed in four previous trials: MIRACLE ICD II,(1) MADIT-CRT,(2) RAFT,(3) and REVERSE.(4) The consistent observed benefits in reverse cardiac remodelling and reduction of heart failure adverse events have resulted in guideline recommendations for CRT in NYHA Class II patients. The guidelines also recommend further studies to determine whether survival is increased by CRT in patients with mild symptoms. The 5-year analysis of the REsynchronization reVErses Remodeling Systolic left vEntricular (REVERSE) trial, which was designed prospectively for 5-year follow-up to specifically assess the long term benefits of CRT, were recently published in the European Heart Journal.(5).

No MeSH data available.


Related in: MedlinePlus